Method of production of nanocapsules of antibiotics in carrageenan

FIELD: nanotechnology.

SUBSTANCE: distinctive feature of the proposed method is the use of antibiotics and the shell of carrageenan nanocapsules, as well as the use of a precipitator - 1,2-dichloroethane in preparation of nanocapsules by physico-chemical precipitation method with nonsolvent.

EFFECT: simplification and acceleration of the process of preparation of nanocapsules and increase in the yield by weight.

10 ex

 

The invention relates to the field of nanotechnology, medicine, pharmacology and veterinary medicine.

Previously known methods for producing microcapsules of drugs. Thus, in the patent 2092155, IPC AC 047/02, AK 009/16, publ. 10.10.1997, the Russian Federation, proposed a method for microencapsulation of drugs, based on the use of special equipment use of irradiation with ultraviolet rays.

The disadvantages of this method are the duration of the process and application of ultraviolet radiation, which can influence the formation of microcapsules.

In the patent 2095055, IPC AC 9/52, AK 9/16, AC 9/10, RF, publ. 10.11.1997, a method of producing a solid non-porous microspheres, which comprises melting pharmaceutically inactive substance carrier, the dispersion of the pharmaceutically active substance in the melt in an inert atmosphere, spraying the resulting dispersion in the form of a mist in the freezing chamber under pressure, in an inert atmosphere, at a temperature of from -15 to -50°C, and separation of the obtained microspheres into fractions by size. The suspension is intended for administration by parenteral injection, contains an effective amount of microspheres distributed in a pharmaceutically acceptable liquid vector, and a pharmaceutically active agent microspheres of nerist�Roman in a specified liquid medium.

Disadvantages of the proposed method are the complexity and duration of the process, the use of special equipment.

In the patent 2076765, IPC B01D 9/02, RF, publ. 10.04.1997, a method of producing dispersed particles of soluble compounds in the microcapsules by means of crystallization from solution, wherein the solution is dispersed in an inert matrix, cooled and, by changing the temperature, get dispersed particles.

The disadvantage of this method is the complexity of: obtaining microcapsules by dispersing followed by a change in temperature, which slows down the process.

In the patent 2101010, IPC AC 9/52, AK 9/50, AK 9/22, AK 9/20, AK 31/19, RF, publ. 10.01.1998 proposed chewable form of the drug with taste masking, having the properties of a controlled release drug product that contains microcapsules with a size of 100-800 microns in diameter and consists of pharmaceutical kernel crystalline ibuprofen and polymeric coating comprising a plasticizer, elastic enough to resist chewing. Polymer coating is a copolymer based on methacrylic acid.

Disadvantages of the invention: use of a copolymer based on methacrylic acid, as these polymer coatings can cause cancer; obtaining mikroC�psul by the method of suspension polymerization; the difficulty of execution; the duration of the process.

In the patent 2139046, IPC AC 9/50, AK 49/00, AK og 51/00, RF, publ. 10.10.1999, a method of producing microcapsules as follows. Emulsion oil-in-water is prepared from an organic solution containing dissolved mono-, di-, triglyceride, preferably of tripalmitin or tristearin and possibly therapeutically active substance, and an aqueous solution containing a surfactant may evaporate the solvent, add redispersible agent and the mixture is subjected to drying by freezing. Subjected to drying, the mixture is then dispersed in an aqueous medium to separate the microcapsules from the remnants of organic matter and a hemispherical or spherical microcapsules are dried.

The disadvantages of the proposed method are the complexity and duration of the process, the use of drying by freezing, which is time consuming and slows down the process of obtaining microcapsules.

In the patent 2159037, IPC A01N 25/28, A01N 25/30, RF, publ. 20.11.2000, a method of producing microcapsules by polymerization reaction at the phase boundary, containing solid agrochemical material of 0.1 to 55 wt.%, suspended in a stirred water organic liquid, from 0.01 to 10 wt.% non-ionic dispersant, is active on the interface and not acting as EMU�igator.

Disadvantages of the proposed method are the complexity, duration, use of vysokokalievogo mixer.

In the article "Development of microencapsulated and gel products and materials for various industries", Russian chemical journal, 2001, vol. XLV, No. 5-6, pp. 125-135, a method for producing microcapsules of drugs by the method of gas-phase polymerization, as the authors believe the chemical method of coacervation of aqueous media for the microencapsulation of drugs due to the fact that most of them are water-soluble. The process of microencapsulation by the method of gas-phase polymerization using n-xylylene includes the following basic stages: vaporization of the dimer of n-xylylene (170°C), thermal decomposition in the pyrolysis furnace (650°C at a residual pressure of 0.5 mm Hg.St.), transfer of the reaction products in the "cold" chamber of polymerization (20°C and a residual pressure of 0.1 mm Hg.St.), deposition and polymerization on the surface of the protected object. The polymerization chamber is made in the form of a rotating drum, the optimal speed for powder coating 30 Rev/min. shell Thickness is controlled by the coating. This method is suitable for the encapsulation of any solids (except prone to intense sublimation). The resulting poly-n-�Ellen - vysokokritichnyh polymer with high orientation and dense packing, provides a conformal coating.

The disadvantages of the proposed method are the complexity and duration of the process, using the method of gas-phase polymerization, which makes the method inapplicable to obtain microcapsules of drugs in polymers protein nature due to denaturation of proteins at high temperatures.

In the article "Development of micro - and nanosystems for drug delivery", Russian chemical journal, 2008, T. LII, No. 1, pp. 48-57, presents a method of producing microcapsules with the included proteins, which is not significantly reduces their biological activity by the process of interfacial crosslinking of soluble starch or hydroxyethyl starch and bovine serum albumin (BSA) using terephthaloyl chloride. A the protease inhibitor Aprotinin, either native or protected active site, was microencapsulated in his introduction to the composition of the aqueous phase. Tapered form lyophilized particles confirm the receipt of microcapsules or particles tank types. The thus prepared microcapsules tear after lyophilization and easily regained their spherical shape after rehydration in buffer environment. The pH of the aqueous phase was defined�known in obtaining robust microcapsules with a high yield.

The disadvantage of the proposed method of obtaining microcapsules is the complexity of the process, and hence the floating output of the target capsules.

In the patent 2173140, IPC AC 009/50, AK 009/127, RF, publ. 10.09.2001, a method of producing kremnijorganicheskih microcapsules using a rotary cavitation equipment with high shear forces and powerful hydroacoustic phenomena sonic and ultrasonic range for dispersion.

The disadvantage of this method is the use of special equipment - rotary-cavitational installation, which has the ultrasonic effect, which influences the formation of the microcapsules and thus may cause adverse reactions due to the fact that ultrasound has a destructive effect on polymers of protein nature, therefore, the proposed method is applicable when working with polymers of synthetic origin.

In the patent 2359662, IPC AC 009/56, A61J 003/07, B01J 013/02, A23L 001/00, publ. 27.06.2009, the Russian Federation, a method of producing microcapsules using spray cooling in the spray tower Niro under the following conditions: air temperature 10°C air temperature at the outlet 28°C, the speed of rotation of the spray drum 10000 rpm/min Microcapsules according to the invention have improved stability and provide adjustable and/or prolongeau�Noe release of the active ingredient.

The disadvantages of the proposed method are the duration of the process and the use of special equipment, certain set of conditions (the air temperature at the inlet 10°C, the temperature at the outlet 28°C, the speed of rotation of the spray drum 10000 rpm).

In the patent WO/2010/076360 ES, IPC 01J 3/00; AC 9/14; AC 9/10; AC 9/12, publ. 08.07.2010, we propose a new method for obtaining solid micro - and nanoparticles with a homogeneous structure with a particle size less than 10 microns, where the treated solids have a natural crystalline, amorphous, polymorphous, and other conditions associated with the reference compound. The method allows to obtain solid micro - and nanoparticles with substantially spheroidal, the morphologists.

The disadvantage of the proposed method is the complexity and duration of the process.

In the patent WO/2010/119041 EP, IPC A23L 1/00, publ. 21.10.2010, a method of producing microspheres comprising an active component encapsulated in the gel matrix whey protein, including denatured protein, the serum and active components. The invention relates to a method of producing microspheres, which contain components such as probiotic bacteria. A method of producing microspheres includes the step of production of microspheres in accordance with the method of the invention and the subsequent solidification of microspheres in Rast�'or is an anionic polysaccharide with a pH of 4.6 and below for at least 10, 30, 60, 90, 120, 180 minutes. Examples of suitable anionic polysaccharides: pectin, alginates, carrageenans. Ideally, whey protein is teplogeneriruyuschim, although other methods of denaturation are also applicable, for example denaturation induced pressure. In a preferred embodiment, the whey protein denatures at a temperature of from 75°C to 80°C appropriately in a period of from 30 minutes to 50 minutes. Typically, whey protein mixed with thermal denaturation. Accordingly, the concentration of the whey protein is from 5 to 15%, preferably from 7 to 12%, and ideally from 9 to 11% (weight/volume). As a rule, the product has to be filtered through multiple filters with a gradual reduction of pore size. Ideally, the fine filter has a submicron pore size, for example from 0.1 to 0.9 microns. The preferred method of producing microspheres is the way with the application encapsulators corresponding vibration (Inotech, Switzerland) and machines production of NISCO stock Engineering AG,. Typically, the nozzles have openings 100 and 600 microns, and ideally about 150 microns.

The disadvantage of this method is the use of special equipment (encapsulators corresponding vibration (Inotech, Switzerland)), obtaining microcapsules by means of protein denaturation, the complexity of the allocation obtained by the method of microcapsules - filtration�I with the use of multiple filters, making the process lengthy.

In the patent WO/2011/003805 EP, IPC B01J 13/18; B65D 83/14; C08G 18/00, publ. 13.01.2011 described a method of producing microcapsules that are suitable for use in the compositions forming sealants, foams, coatings or adhesives.

The disadvantage of the proposed method is the use of centrifugation for separation from the process fluid, the duration of the process, and the application of this method in the pharmaceutical industry.

In patents 20110223314, IPC B05D 7/00, 20060101 B05D 007/00, VS 3/02, 20060101 VS 003/02; VS 11/00, 20060101 VS 011/00; B05D 1/18, 20060101 B05D 001/18; B05D 3/02, 20060101 B05D 003/02; B05D 3/06 20060101 B05D 003/06 from 10.03.2011, US, describes a method of producing microcapsules by the method of suspension polymerization, belonging to the group of chemical methods with the use of a new device and UV exposure.

The disadvantage of this method are the complexity and duration of the process, the use of special equipment, the use of UV irradiation.

In the patent WO/2011/150138, US, IPC C11D 3/37; B01J 13/08; C11D 17/00, publ. 01.12.2011 described a method of producing microcapsules of a solid water-soluble agents polymerization.

The disadvantages of this method are the complexity and duration of the process.

In the patent WO/2011/127030, US, IPC AC 8/11; B01J 2/00; B01J 13/06; C11D 3/37; C11D 3/39; C11D 17/00, publ. 13.10.2011 proposed several ways of obtaining �of microcapsule: interfacial polymerization, thermoinduced the phase separation, spray drying, evaporation of the solvent, etc.

The disadvantages of the proposed methods is the difficulty, duration of processes, and the use of special equipment (filter (Albet, Dassel, Germany), spray dryer for collecting particles (Spray-M Dryer from Losert, Belgium)).

In the patent WO/2011/104526, GB, IPC B01J 13/00; B01J 13/14; SV 67/00; C09D 11/02, publ. 01.09.2011, a method of producing a dispersion of encapsulated solid particles in a liquid medium, comprising: a) grinding composition, including solid, liquid medium and a polyurethane dispersant with an acid number of from 0.55 to 3.5 mmol per gram of dispersant, said composition includes 5 to 40 parts of the polyurethane dispersant per 100 parts of solid product by weight; and b) crosslinking the polyurethane dispersant in the presence of solid and liquid medium so as to encapsulate the solid particles which the polyurethane dispersant contains less than 10% by weight of recurring items from polymer alcohols.

The disadvantages of the proposed method are the complexity and duration of the process of production of microcapsules, and that the encapsulated particles by the proposed method are useful as colorants in inks, especially ink jet printing, for the pharmaceutical industry this practice is not applicable.

p> In the patent WO/2011/056935 US, IPC C11D 17/00; AC 8/11; B01J 13/02; C11D 3/50, publ. 12.05.2011, a method for producing microcapsules with a size of 15 microns. As the shell material of the proposed polymers of the group consisting of polyethylene, polyamides, polystyrene, polyisoprenes, polycarbonates, polyesters, polyacrylates, polyureas, polyurethanes, polyolefins, polysaccharides, epoxy resins, vinyl polymers and mixtures thereof. Proposed polymeric membranes are relatively impermeable to the core material and materials in the environment in which the encapsulated benefit agent will be used to provide benefits that will be received. The core of the encapsulated agents may include perfume, silicone oils, waxes, hydrocarbons, higher fatty acids, essential oils, lipids, cooling the skin fluids, vitamins, sunscreens, antioxidants, glycerine, catalysts, bleach particles, particles of silicon dioxide, etc.

The disadvantages of the proposed method are the complexity, the duration of the process, using as the shells of the microcapsules of polymers of synthetic origin and their mixtures.

In the patent WO/2011/160733 EP, IPC B01J 13/16, publ. 29.12.2011, a method for producing microcapsules which contain a shell and core water-insoluble materials. The aqueous solution of protective colloide a mixture of at least two structurally different bifunctional diisocyanates (A) and (B), insoluble in water, gather together before the formation of the emulsion, is then added to a mixture of bifunctional amine and heated to a temperature of at least 60°C before the formation of the microcapsules.

The disadvantages of the proposed method are the complexity, the duration of the process, using as the shells of the microcapsules of polymers of synthetic origin and their mixtures.

The closest method is the method proposed in the patent 2134967, IPC A01N 53/00, A01N 25/28, publ. 27.08.1999, Russia, (1999). In water dispersed solution of a mixture of natural lipids and PYRETHROID insecticide in a weight ratio of 2-4: 1 in an organic solvent, which leads to simplification of the method of microencapsulation.

The disadvantage is the dispersion in an aqueous medium, which makes the proposed method applicable for obtaining microcapsules of water-soluble drugs in water-soluble polymers.

The technical objective is the simplification and acceleration of the process of producing nanocapsules of antibiotics in carrageenan, reduction of losses in obtaining nanocapsules (increase of the yield by weight).

The solution of a technical problem is achieved by a method of obtaining nanocapsules of antibiotics, characterized in that as the shell of the microcapsules used carrageenan, as well as obtaining nanocapsules physico-chemical method of deposition of nerastvorim with and�the use of precipitator - 1,2-dichloroethane, the process is carried out without special equipment.

A distinctive feature of the proposed method is the use as the shell of the nanocapsules of antibiotics carrageenan, as well as obtaining nanocapsules physico-chemical method of deposition of nerastvorim using precipitator - 1,2-dichloroethane.

The result of the proposed method are obtaining nanocapsules antibiotics, carageenan at 25°C for 15 minutes. The output of the microcapsules is 100%.

EXAMPLE 1 Obtaining nanocapsules of Ceftriaxone in the carrageenan, the ratio of core:shell 1:3

To a suspension of 1.5 g of carrageenan in isopropanol and 0.01 g of the drug A with (an ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid, and citric acid as tribasic can be etherification other glycerides and as oxanilate - other fatty acids. Free acid groups can be neutralized with sodium) as a surfactant in the small portions add 0.5 g of Ceftriaxone powder. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nanocapsules was filtered off and dried.

Received 2 g of a white powder. The yield was 100%.

EXAMPLE 2 Obtaining nanocapsules Cefazolin in the carrageenan, the ratio I�Rho:shell 1:3

To a suspension of 1.5 g of carrageenan in isopropanol and 0.01 g of the drug as a surfactant is added 0.5 g of Cefazolin powder. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nanocapsules was filtered off and dried.

Received 2 g of a white powder. The yield was 100%.

EXAMPLE 3 Obtaining nanocapsules of cefepime in the carrageenan, the ratio of core:shell 1:3

To a suspension of 1.5 g of carrageenan in isopropanol and 0.01 g of the drug A with (an ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid, and citric acid as tribasic can be etherification other glycerides and as oxanilate - other fatty acids. Free acid groups can be neutralized with sodium) as a surfactant, was added 0.5 g of cefepime powder. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nanocapsules was filtered off and dried.

Received 2 g of a white powder. The yield was 100%.

EXAMPLE 4 Obtaining nanocapsules Cefotaxime in the carrageenan, the ratio of core:shell 1:3

To a suspension of 1.5 g of carrageenan in isopropanol and 0.01 g of the drug A with as surfactant is added 0.5 g of powder Cefotaxime. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nano�Apso filtered off and dried.

Received 2 g of a white powder. The yield was 100%.

EXAMPLE 5 Obtaining nanocapsules of amikacin in the carrageenan, the ratio of core:shell 1:3

To a suspension of 1.5 g of carrageenan in isopropanol and 0.01 g of the drug A with as surfactant is added 0.5 g of powder amikacin. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nanocapsules was filtered off and dried. Received 2 g of a white powder. The yield was 100%.

EXAMPLE 6 Obtaining nanocapsules sodium salt of benzylpenicillin in the carrageenan, the ratio of core:shell 1:3

To a suspension of 1.5 g of carrageenan in isopropanol and 0.01 g of the drug A with as surfactant is added 0.5 g of a powder of sodium salt of benzylpenicillin. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nanocapsules was filtered off and dried.

Received 2 g of a white powder. The yield was 100%.

EXAMPLE 7 Obtaining nanocapsules of streptocid carrageenan, the ratio of core:shell 1:3

To a suspension of 1.5 g of carrageenan in isopropanol and 0.01 g of the drug A with as surfactant is added 0.5 g of sulfanilamide powder. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nanocapsules was filtered off and dried.

Received 2 g of a white powder. The yield was 100%.

EXAMPLE 8 Obtaining nanocapsules ampicill�on in carrageenan, the ratio of core:shell 1:3

To a suspension of 1.5 g of carrageenan in isopropanol and 0.01 g of the drug A with as surfactant is added 0.5 g of ampicillin powder. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nanocapsules was filtered off and dried.

Received 2 g of a white powder. The yield was 100%.

EXAMPLE 8 Obtaining nanocapsules kanamycin in the carrageenan, the ratio of core:shell 1:3

To a suspension of 1.5 g of carrageenan in isopropanol and 0.01 g of the drug A with as surfactant is added 0.5 g of kanamycin powder. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nanocapsules was filtered off and dried.

Received 2 g of a white powder. The yield was 100%.

EXAMPLE 9 Obtaining nanocapsules of streptomycin in the carrageenan, the ratio of core:shell 1:3

To a suspension of 1.5 g of sodium alginate in isopropanol and 0.01 g of the drug A with as surfactant is added 0.5 g of powder of streptomycin. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nanocapsules was filtered off and dried.

Received 2 g of a white powder. The yield was 100%.

EXAMPLE 10 Obtaining nanocapsules bicillin-3 in the carrageenan, the ratio of core:shell 1:3

To a suspension of 1.5 g of carrageenan in isopropanol and 0.01 g of the drug A with as superficial�-active substance is added 0.5 g of a powder of bicillin-3. Then added dropwise 5 ml of 1,2-dichloroethane. The resulting suspension of nanocapsules was filtered off and dried.

Received 2 g of a white powder. The yield was 100%.

The obtained nanocapsules of antibiotics in the carrageenan physico-chemical deposition method by nerastvorim using 1,2-dichloroethane as nerastvorimaya. The process is simple to perform and lasts for 15 minutes, requires no special equipment.

The proposed method is suitable for the pharmaceutical industry due to the minimal loss of speed, ease of obtaining and allocation of nanocapsules of antibiotics in the carrageenan.

A method of producing nanocapsules of antibiotics, characterized in that as the shell is used carrageenan, which is precipitated from isopropanol in the presence of an ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid as a surfactant by adding 1,2-dichloroethane as a precipitator, and wherein the drying of the suspension obtained nanocapsules occurs at 25C.



 

Same patents:

FIELD: nanotechnology.

SUBSTANCE: distinctive feature of the proposed method is the use of antibiotics and the shell of nanocapsules of gellan gum, as well as the use of a precipitator - diethyl ester in preparing the nanocapsules by physico-chemical method of precipitation by nonsolvent.

EFFECT: simplification and acceleration of the process of preparing the nanocapsules and increase in the yield by weight.

10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a method for producing preparation microcapsules possessing supramolecular properties by non-solvent addition differing by the fact that a preparation is iron sulphate or zinc sulphate pre-dissolved in water, whereas a coating is sodium alginate deposited from a butanol solution by adding ethanol as a non-solvent and water, which is followed by drying at room temperature.

EFFECT: invention provides facilitating and accelerating the microencapsulation process, as well as lowered accompanying loss (higher weight yield).

3 ex, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a method for producing microcapsules possessing supramolecular properties by non-solvent addition differing by the fact that a microcapsule nucleus is trivitamin dissolved in dimethylsulphoxide, whereas a coating is xanthan gum deposited from a butanol solution by adding toluene as a non-solvent and water, which is followed by drying at room temperature.

EFFECT: invention provides facilitating the preparation microencapsulation in water-soluble polymers and higher weight yield.

4 ex, 6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a method for drug preparation encapsulation by non-solvent addition differing by the fact that fenbendazole is used as a microcapsule nucleus, whereas a microcapsule coating is sodium carboxymethyl cellulose; herewith fenbendazole 100 mg is dissolved in dimethylsulphoxide, or dioxane, dimethylformamide 1 ml; the prepared mixture is dispersed in a sodium carboxymethyl cellulose solution in isopropanole containing the above polymer 300 mg in the presence of E472c surfactant 0.01 g, and stirred at 1000 rps, added with butanol 2 ml and distilled water 1 ml; the prepared suspension of microcapsules is filtered and dried at 25°C.

EFFECT: invention provides facilitating and accelerating the microencapsulation process, as well as lowered accompanying loss (higher weight yield).

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents method of obtaining microcapsules of medication, which possess supermolecular properties, by method of precipitation with non-solvent, characterized by the fact that as medication applied is powder of unabi berries, preliminarily dissolved in butanol, as envelope - carrageenan, which is precipitated from solution in acetone by addition as non-solvent of ethanol and water, with the following drying at room temperature.

EFFECT: invention ensures simplification and acceleration of process of obtaining microcapsules, reduction of loss in the process of obtaining microcapsules (increase of output by weight).

2 ex, 18 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of chemical-pharmaceutical industry and represents method of obtaining microcapsules, which have supermolecular properties, by method of precipitation with non-solvent, characterised by the fact that as a core of microcapsules flavor "apple", preliminarily dissolved in butanol, is applied, as casing - carrageenan, which is precipitated from solution in isopropanol by addition as non-solvent of butanol and water, with the following drying at room temperature.

EFFECT: invention ensures simplification and acceleration of process of obtaining microcapsules, reduction of loss in the process of obtaining microcapsules (increase of output by weight).

1 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: invention provides a method of encapsulating a medicinal preparation via nonsolvent deposition, characterised by that the core of the microcapsules used is fenbendazole, which is pre-dissolved in dioxane or dimethylsulphoxide, the envelope used is sodium carboxymethyl cellulose which is deposited from a solution in carbinol by adding, as the nonsolvent, isopropanol and water at 25°C.

EFFECT: simple and faster process of producing microcapsules, reduced losses when producing microcapsules, high mass output.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents method of medication encapsulation by precipitation with non-solvent, which is characterised by the fact that as medication used is fenbendazole, and as envelope - sodium carboxymethylcellulose, which is precipitated from solution in acetone by addition as non-solvent of methylcarbinol and water at 25°C.

EFFECT: invention ensures simplification and acceleration of process of obtaining microcapsules, reduction of loss in obtaining microcapsules (increase of output by weight).

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents method of medication encapsulation of by method of sedimentation with non-solvent, which is characterised by the fact that as medication applied is acridonacetic acid, and as envelope sodium carboxymethylcellulose, which is precipitated from solution in hexane by addition as non-solvent of methanol and water at 25°C.

EFFECT: invention ensures simplification and acceleration of process of obtaining microcapsules, reduction of loss in obtaining microcapsules (increase of output by weight).

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents method of medication encapsulation by precipitation with non-solvent, which is characterised by the fact that as medication used is fenbendazole, and as envelope - sodium carboxymethylcellulose, which is precipitated from solution in ethylacetate by addition as non-solvent of carbinol and water at 25°C.

EFFECT: invention ensures simplification and acceleration of process of obtaining microcapsules, reduction of loss in obtaining microcapsules (increase of output by weight).

3 ex

FIELD: nanotechnology.

SUBSTANCE: distinctive feature of the proposed method is the use of antibiotics and the shell of nanocapsules of gellan gum, as well as the use of a precipitator - diethyl ester in preparing the nanocapsules by physico-chemical method of precipitation by nonsolvent.

EFFECT: simplification and acceleration of the process of preparing the nanocapsules and increase in the yield by weight.

10 ex

FIELD: biotechnology.

SUBSTANCE: method comprises successive culturing in the growth and storage media where the growth medium comprises 5.0 wt % cattle serum and nutrient medium Igla MEM, and the storage medium comprises 49.0-80.0 mg/L proline, 40.0-60.0 mg/L glycine, and a mixture of equal parts of DMEM and F-12 media. Based on thus obtained substance of recombinant erythropoietin its nanocapsular form is prepared.

EFFECT: invention enables to obtain a substance of erythropoietin with increased specific activity and free from extraneous protein impurities and suitable for nanocapsulation, to simplify the technology of its production.

3 cl, 5 dwg, 1 tbl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing a magnet-sensitive lipid composition. The declared method involves preparing a therapeutic agent containing cisplatin, a source of phospholipids and a magnetism carrier representing pirocarbon-coated ferric nanoparticles to be exposed to UV radiation. The above phospholipid source is the pharmacopeial drug 'Phosphogliv' with the composite prepared in the micellar form.

EFFECT: providing the uniformity and thermodynamic stability of the composite prepared over a short optimum period of time with using no organic solvents.

1 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to surface-modified particles, and methods for preparing and using, pharmaceutical suspensions containing said surface-modified particles, and a method for enhancing the active agent internalisation. The surface-modified particles comprise a particle core and a coating coupled with the particle core; the above coating is absorbed on the surface of the particle core wherein the particle core contains a therapeutic agent; the coating contains opsonin, and the surface-modified particle has an average particle size from approximately 1 nm to 2000 nm, and said opsonin is specified in proteins and peptides which bind to the particles or cells so that the phagocytosis ability of the particles or cells increases, wherein pH of the opsonin solution is below an isoelectric point of opsonin.

EFFECT: developing the method for enhancing the active agent internalisation.

35 cl, 11 dwg, 3 tbl, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, more specifically to polymer nanoparticles with hydrophobic nucleus and hydrophilic coating prepared of N-isopropylacrylamide (NIPAAM), water-soluble vinyl derivatives, such as vinyl pyrrolidone (VP) or vinylacetate (VA), or water-insoluble vinyl derivatives, such as methyl methacrylate (MMA) or styrene (ST) for specific delivery systems, such as oral and enteral ones. The polymer nanoparticles enable delivering various drugs or biologically active agents within the oral, parenteral or local routes of administration.

EFFECT: implementing the invention enables formulating poorly water-soluble drug preparations or biologically active agents or other agents with poor oral availability in an aqueous solution, thereby allowing for the systemic circulation delivery.

64 cl, 12 dwg, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a composition for nicotinic immunonanotherapy containing synthetic nanocarriers having a polymeric surface conjugated with a variety of nicotine residues with the variety of the nicotinic residues on the nanocarrier form an immunogenic surface providing a low affinity, a high-avidity binding of the nicotinic residues to the surfaces of an antigen presenting cell (APC) compared with an antibody binding, and a pharmaceutically acceptable excipient. The invention provides the nanocarriers capable to stimulate an immune response in T-cells and/or B cells and to produce the antinicotin antibodies with the humoral and cellular response to be achieved in the absence of an exogenous adjuvant.

EFFECT: invention provides the absence of the non-specific response on an inflammation caused by an adjuvant.

17 cl, 37 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used for cancer treatment. For this purpose efficient quantity of pharmaceutical composition, which contains nanoparticles, containing rapamycin and carrier protein is introduced to patient, quantity of rapamycin in composition constitutes from approximately 54 mg to approximately 540 mg. Group of inventions also relate to single dosage form, which contains said composition and pharmaceutically acceptable carrier, and to for cancer treatment.

EFFECT: application of claimed composition makes it possible to suppress, stabilise and/or delay cancer development and additionally provides methods of combined therapy for cancer treatment.

81 cl, 1 tbl, 6 dwg, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is the use of L-carnosine for making a nanopreparation having antihypoxic and antioxidant activity combined with a combination of substances selected from the group of phospholipids, non-polar lipids in the following ratio, wt %: L-carnosine - 1.1-1.2, non-polar lipids such as triglycerides, cholesterol, free fatty acids, DL-α-Tocopherol - 1.2-2.5, phospholipids such as phosphatidylcholine, phosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylethanolamine, sphingomyelin - 95.3-96.3 for preparing a drug having antihypoxic and antioxidant activity. The drug can be presented in the form of liposomes containing L-carnosine.

EFFECT: invention provides higher stability of L-carnosine and its lifetime up to three days with underlying higher effectiveness in small doses, as well as to improve the cerebral ischemia tolerance, the recovery after acute hypoxia and to increase the antioxidant status of the brain tissue.

3 cl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared group of inventions refers to a pharmacological composition for intranasal introduction for cerebral delivery, and a method for preparing said composition. The declared composition comprises a container base formed by porous particles of calcium carbonate and titanium dioxide of particle size 100-5000 nm and a pharmacologically active component - loperamide. The container surface is modified by surfactants specified in polysorbates, or by polymers specified in a group containing glycosaminoglycanes and polypeptides, or their combination. A method for preparing the pharmacological composition consists in preparing the container base by porous particle synthesis, sorption of loperamide in its pore spaces and modification of the container surface by polymers and surfactants by container incubation in their solutions.

EFFECT: invention provides preparing the pharmacological composition which is applicable for cerebral loperamide delivery after the intranasal introduction.

5 cl, 5 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention includes compositions and methods for obtaining activated polymer nanoparticles for targeted delivery of medication. Nanoparticle includes biocompatible polymer and amphiphilic stabilising agent, non-covalently bound with linker, which includes, at least, one elecrophile, selectively reacting with any nucleophile on targeting substance, and places targeting substance on external surface of biodegradable nanoenvelope, active substance being loaded into nanoenvelope. Biocompatible po;ymer includes one or several polyesters, selected from group, containing polylactic acid, polyglycolic acid, copolymer of lactic and glycolic acids and their combinations. Amphiphilic stabilising agent includes polyol. Active substance represents anti-cancer medication, preferably, curcumin.

EFFECT: invention ensures delivery of therapeutic substance to the place of its action.

27 cl, 11 dwg, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of encapsulation, in particular to method of obtaining microcapsules Biopag-D in envelope of human leukocytic interferon (β- or α-interferon). According to invention method, suspension of Biopag-D in water is added to 1-% water solution of interferon in presence of medication E472c and mixed to transparent solution. Suspension of Biopag-D and interferon solution are taken in weight ratio 3:1 or 2.5:1. Butanol, and then acetone taken in ratio 1:5% vol/vol are added. Obtained suspension of microcapsules is filtered, washed and dried. Process of obtaining microcapsules is realised at 25°C for 15 min.

EFFECT: invention ensures simplification and acceleration of process of obtaining microcapsules, reduction of loss in the process of their obtaining (increase of output by weight).

3 ex

Up!